A SAD Study of ZT002 Injection in Healthy Participants
Status:
COMPLETED
Trial end date:
2023-12-08
Target enrollment:
Participant gender:
Summary
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.